Global Pharmacogenomics Market Segmentation, By Product and Service (Kits and Reagents and Services), Disease Area (Cancer, Cardiovascular, Neurological Diseases, and Other Disease Areas), Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, and Mass Spectrometry), Application (Drug Discovery, Neurology, Oncology, Pain Management, and Others), End-Users (Hospitals, Research Organisation, and Others) – Industry Trends and Forecast to 2031
Pharmacogenomics Market Analysis
The pharmacogenomics market is experiencing significant growth, driven by advancements in personalized medicine and the increasing recognition of the role genetics play in drug efficacy and safety. Recent developments in this field include the integration of next-generation sequencing (NGS) technologies and bioinformatics tools, which enhance the ability to analyze genetic variations that affect drug response. For instance, companies such as Oxford Nanopore Technologies are launching innovative programs to combine their sequencing platforms with other genomic technologies, thereby facilitating the development of tailored treatment plans. Additionally, healthcare institutions, such as Nicklaus Children's Hospital, are adopting pharmacogenomics technologies to create personalized therapies, minimizing adverse drug reactions and optimizing therapeutic outcomes. The rise of collaborations between pharmaceutical companies and biotech firms is further propelling the market, as these partnerships aim to develop new pharmacogenomic tests and applications. Regulatory bodies are also supporting this growth by promoting the use of genetic testing in clinical settings, ensuring safer and more effective medication choices. Overall, the pharmacogenomics market is poised for continued expansion, with ongoing innovations enhancing the precision of healthcare delivery.
Pharmacogenomics Market Size
The global pharmacogenomics market size was valued at USD 8.69 billion in 2023 and is projected to reach USD 19.74 billion by 2031, with a CAGR of 10.80% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pharmacogenomics Market Trends
“Increasing Adoption of Next-Generation Sequencing (NGS) Technologies”
The pharmacogenomics market is experiencing significant growth, driven by advancements in personalized medicine and the increasing recognition of the role genetics play in drug efficacy and safety. One notable trend in the pharmacogenomics market is the increasing adoption of next-generation sequencing (NGS) technologies to enhance personalized medicine. NGS allows for the rapid and comprehensive analysis of genetic variations that influence drug metabolism and efficacy, enabling healthcare providers to tailor treatments to individual patients based on their genetic profiles. For instance, companies such as Illumina are at the forefront of this trend, offering advanced sequencing platforms that facilitate the identification of genetic markers associated with various diseases. As more healthcare institutions recognize the value of NGS in pharmacogenomics, the demand for genetic testing is expected to surge. This trend is further supported by growing collaborations between pharmaceutical companies and diagnostic firms, aimed at developing targeted therapies that minimize adverse drug reactions and improve patient outcomes. By integrating NGS into clinical practice, the pharmacogenomics market is paving the way for a more personalized approach to medication management, ultimately enhancing the effectiveness of treatments while reducing costs associated with trial-and-error prescribing.
Report Scope and Pharmacogenomics Market Segmentation
|
Attributes
|
Pharmacogenomics Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Novartis AG (Switzerland), Viatris Inc. (U.S.), Ferndale Pharma Group, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca (U.K.), GSK plc (U.K.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Merck & Co., Inc. (Germany), Sun Pharmaceutical Industries Ltd. (India), NATCO Pharma Limited (India), Lupin (India), Teva Pharmaceutical Industries Ltd (Israel), Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (U.S.), Abbott (U.S.), and Bayer AG (Germany)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Pharmacogenomics Market Definition
Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. It combines pharmacology (the study of drugs) and genomics (the study of genes and their functions) to understand how genetic variations affect drug metabolism, efficacy, and safety. By analyzing a person's genetic profile, pharmacogenomics aims to tailor drug therapies to optimize treatment outcomes, minimize adverse effects, and improve overall healthcare by ensuring that patients receive the most appropriate medications based on their unique genetic characteristics.
Pharmacogenomics Market Dynamics
Drivers
- Rising Incidence of Adverse Drug Reactions (ADRs)
The rising incidence of adverse drug reactions (ADRs) has become a significant concern in healthcare, prompting increased awareness and demand for pharmacogenomic testing. According to the World Health Organization, ADRs account for 5–10% of hospital admissions and can lead to extended hospital stays, increased healthcare costs, and even fatalities. A study published in the Journal of the American Medical Association highlighted that around 2 million serious ADRs occur annually in the U.S., with nearly 100,000 resulting in death. This alarming trend underscores the importance of understanding the genetic variations that influence drug metabolism and response. Pharmacogenomic testing enables healthcare providers to identify patients at risk for ADRs by analyzing specific genetic markers, allowing for more tailored medication choices. For instance, individuals with variations in the CYP2D6 gene may metabolize certain medications, such as antidepressants and opioids, differently, increasing their risk of experiencing severe side effects. By integrating pharmacogenomic insights into clinical practice, healthcare professionals can significantly minimize the risks associated with ADRs, improve patient safety, and enhance treatment efficacy, ultimately driving the market growth.
- Growing Prevalence of Various Disorders
The growing prevalence of various disorders is a significant driver for the pharmacogenomics market, as it underscores the need for personalized medicine tailored to individual patient profiles. According to the World Health Organization (WHO), chronic diseases such as cancer, diabetes, and cardiovascular diseases are on the rise, accounting for over 70% of global deaths annually. For instance, the American Cancer Society estimates that in 2023, about 1.9 million new cancer cases will be diagnosed in the United States alone, highlighting an urgent need for effective treatment options that consider genetic factors influencing drug efficacy and safety. Similarly, the prevalence of diabetes has surged, with the International Diabetes Federation reporting that approximately 537 million adults are living with the condition worldwide, a number projected to rise to 783 million by 2045. Such increasing burden of disorders amplifies the demand for pharmacogenomic testing, as it enables healthcare providers to better understand how genetic variations affect individual responses to medications. By leveraging pharmacogenomic insights, clinicians can optimize treatment plans, reduce trial-and-error prescribing, ultimately driving the market growth.
Opportunities
- Increasing Supportive Government Policies
Supportive government policies and initiatives play a crucial role in promoting the integration of pharmacogenomics into clinical practice, thereby enhancing personalized medicine. For instance, in the United States, the National Institutes of Health (NIH) has launched the All of Us Research Program, which aims to gather health data from one million participants to advance precision medicine, including pharmacogenomic research. Additionally, the Food and Drug Administration (FDA) has been actively supporting the development of pharmacogenomic tests by issuing guidelines and creating databases, such as the Table of Pharmacogenomic Biomarkers in Drug Labeling, to inform healthcare providers about genetic factors affecting drug responses. Similarly, countries such as Canada and Australia have initiated funding programs to foster research into pharmacogenomics and encourage its application in clinical settings. These government-backed initiatives provide the necessary resources for research and development create an environment conducive to collaboration among academia, industry, and healthcare providers, ultimately driving the adoption of pharmacogenomic testing and improving patient care outcomes.
- Increasing Awareness of Personalized Medicine
Increasing awareness of personalized medicine is significantly propelling the growth of the pharmacogenomics market, as more consumers seek tailored healthcare solutions that cater to their individual genetic profiles. Such heightened awareness is largely fueled by educational initiatives and successful case studies showcasing the benefits of personalized treatment plans, which can lead to better health outcomes and reduced adverse drug reactions. For instance, the use of pharmacogenomic testing in oncology has gained attention, allowing oncologists to select targeted therapies based on the genetic mutations present in a patient's tumor. Companies like Myriad Genetics have pioneered tests that identify actionable mutations, guiding healthcare providers in choosing the most effective treatments for conditions like breast and lung cancer. As patients become more informed and empowered in their healthcare decisions, the demand for pharmacogenomics services is expected to rise, prompting healthcare providers to integrate these solutions into clinical practice and further creating opportunities in the market.
Restraints/Challenges
- High Costs Associated of Testing
The high costs associated with pharmacogenomic testing present a significant barrier to its widespread adoption, impacting both patients and healthcare systems. For instance, the price of genetic tests can range from several hundred to several thousand dollars, depending on the complexity of the analysis and the number of genes assessed. In addition to the test costs, there may also be associated healthcare expenses, such as consultations with specialists and follow-up care, which can further strain patients' finances. Consequently, limited access to these essential services affects individual patient care and also impede the overall advancement of personalized medicine within healthcare systems, ultimately hampering the overall market growth.
- Data Privacy Concerns
Data privacy concerns surrounding genetic testing significantly impact patient willingness to participate in pharmacogenomic studies. The collection and management of sensitive genetic information raise ethical issues related to how this data is stored, shared, and potentially misused. Many individuals fear that their genetic data could be accessed by unauthorized parties, leading to discrimination in employment or insurance based on genetic predispositions. Such apprehension can deter patients from undergoing genetic testing, even when such tests could lead to tailored and more effective treatment options. Furthermore, incidents of data breaches, such as the 2021 ransomware attack on a healthcare provider that compromised sensitive patient data, exacerbate these fears. As a result, the pharmacogenomics market faces challenges in building patient trust and ensuring robust data protection measures are in place to encourage broader participation in genetic testing initiatives.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Pharmacogenomics Market Scope
The market is segmented on the basis of product and service, disease area, technology, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Service
- Kits and Reagents
- Sequencing Kits and Reagents
- PCR Kits and Reagents
- Microarray Kits and Reagents
- Other Kits and Reagents
- Services
Disease Area
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Other Disease Areas
Technology
- DNA Sequencing
- Microarray
- Polymerase Chain Reaction
- Electrophoresis
- Mass Spectrometry
Application
- Drug Discovery
- Neurology
- Oncology
- Pain Management
- Others
End-Users
- Hospitals
- Research Organizations
- Others
Pharmacogenomics Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, product and service, disease area, technology, application, and end user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America holds a leading position in the pharmacogenomics market, both in terms of market share and revenue, and is expected to maintain this dominance throughout the forecast period. This is primarily attributed to the concentration of major industry players in the region, alongside a robust healthcare infrastructure that facilitates advanced research and development. Additionally, the growing emphasis on early diagnosis for improved treatment outcomes, coupled with supportive reimbursement policies, further enhances the market's growth prospects in North America.
Asia-Pacific region is anticipated to experience the fastest growth rate during the forecast period, driven by a rising incidence of gastrointestinal disorders among the population. This surge in cases has prompted governments to enhance healthcare initiatives and support, creating a more favorable environment for pharmacogenomics development. Furthermore, increasing investments in healthcare infrastructure and research are expected to accelerate advancements in personalized medicine, further propelling market growth in this dynamic region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Pharmacogenomics Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Pharmacogenomics Market Leaders Operating in the Market Are:
- Novartis AG (Switzerland)
- Viatris Inc. (U.S.)
- Ferndale Pharma Group, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Lilly (U.S.)
- Merck & Co., Inc. (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- NATCO Pharma Limited (India)
- Lupin (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- Boehringer Ingelheim International GmbH (Germany)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- Bayer AG (Germany)
Latest Developments in Pharmacogenomics Market
- In May 2024, Oxford Nanopore Technologies launched a new Pharmacogenomics (PGx) Beta Program aimed at advancing personalized medicine by integrating Twist Bioscience’s next-generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform
- In February 2024, Nicklaus Children's Hospital in South Florida implemented the next-generation pharmacogenomics technology, specifically the Applied Biosystems PharmacoScan Solution and GeneTitan MC Fast Scan Instrument, to create personalized treatment plans for patients, thereby minimizing complications from drug interactions and side effects
- In July 2023, Illumina Inc. formed a partnership with Pillar Biosciences Inc. to incorporate Pillar's oncology assays into Illumina's global oncology product offerings. This collaboration will merge various next-generation sequencing solutions, resulting in an exceptional array of complementary tools. The advancements in sequencing methodologies are expected to enhance the efficiency, accuracy, and cost-effectiveness of oncology testing, ultimately aiming to expand patient access to personalized cancer treatment alternatives
- In April 2023, Integrated DNA Technologies, Inc. completed the acquisition of Archer NGS research assays from Invitae Corporation, enhancing the xGen NGS product lineup and accelerating oncology research, particularly in the identification of new cancer fusions. This integration into IDT's extensive xGen NGS portfolio provides researchers with streamlined solutions for uncovering critical biomarkers, especially those related to significant cancer fusions
- In January 2023, QIAGEN announced the acquisition of Verogen, a company specializing in next-generation sequencing (NGS) technologies for human identification (HID) and forensic application
SKU-